SGO

Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer

Retrieved on: 
Martedì, Marzo 1, 2022
Gynaecology, ALKS, Schizophrenia, SGO, Neurodegeneration, IV, Science, University, Merck & Co., Alkermes (company), Safety, Bipolar I disorder, Gynecologic Oncology (journal), Peritonitis, Obstetrics, Merck Sharp & Dohme Federal Credit Union, Poster, Ovarian cancer, Society of Gynecologic Oncology, Opioid, Cancer, Immunotherapy, Merck, Research, Program, Society, Obstetrics and gynaecology, Trial of the century, Pembrolizumab, Pharmaceutical industry, Vaccine, Alkermes, Patient

DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022. New data in patients with platinum-resistant ovarian cancer from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of intravenously administered (IV) nemvaleukin as a monotherapy and in combination with pembrolizumab (KEYTRUDA®), will be presented in an oral plenary session. In addition, a trial-in-progress poster from the ongoing ARTISTRY-7 global phase 3 study will be presented. ARTISTRY-7 is evaluating the anti-tumor activity and safety of IV nemvaleukin in combination with pembrolizumab compared to investigator's choice chemotherapy, in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Key Points: 
  • DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022.
  • In addition, a trial-in-progress poster from the ongoing ARTISTRY-7 global phase 3 study will be presented.
  • The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Lunedì, Febbraio 28, 2022
DARS, HER2, Silicon, ATM, Security (finance), Therapy, Company, Mouse, B7-H4, IND, Private Securities Litigation Reform Act, Silicon Valley Bank, MRSN, Research, Society, The Boston Globe, Partnership, Drug discovery, SGO, Safety, Disease, Gynecologic Oncology (journal), U.S. Securities and Exchange Commission, BLA, Tams, Breast, Sodium-dependent phosphate transport protein 2B, Maintenance, CHMP, Ovarian cancer, Population, Therapeutic index, Society of Gynecologic Oncology, NASDAQ, Hand, Neoplasm, Cancer, Oxford, Platinum, Forward-looking statement, Patient, Carboplatin, SVB, ADC, GLOBE, Investor, Achievement, Investigational New Drug, Control, Clinical trial, DAR, FDA, Conference, Tumor microenvironment, SEC, Bank, Fine chemical, Pharmaceutical industry, Birth control, Cryptocurrency, Janssen

Research and development expenses for the fourth quarter of 2021 were $37.4 million, compared to $22.9 million for the same period in 2020.

Key Points: 
  • Research and development expenses for the fourth quarter of 2021 were $37.4 million, compared to $22.9 million for the same period in 2020.
  • Weighted average common shares outstanding for the quarter ended December 31, 2021, and December 31, 2020, were 71,921,322 and 68,630,078, respectively.
  • ET to report financial results for the fourth quarter and full year 2021 and provide certain business updates.
  • Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe.

ImmunoGen Reports Recent Progress and 2021 Financial Results

Retrieved on: 
Venerdì, Febbraio 25, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Head, Security (finance), ID, COVID-19, FACP, CMC, IND, Society of Gynecologic Oncology, Chemistry, Capital expenditure, Research, Society, Board, SGO, Medical Affairs Bureau, Azacitidine, AML, ImmunoGen, Initiate, Sale, Jazz Pharmaceuticals, Gynecologic Oncology (journal), U.S. Securities and Exchange Commission, Medicine, BLA, Food, György Enyedi (geographer), Leadership, Maintenance, Director, Ovarian cancer, Population, MPH, Bevacizumab, Eli Lilly and Company, US Foods, IMGN, Patient, Carboplatin, Control, Clinical trial, ASH, Venetoclax, FDA, Lilly, Cancer, Vaccine, Management, Pharmaceutical industry, Platinum, Risk management, Online gambling, Airline, Company, BPDCN, Huadong Medicine, MD

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.
  • Together with the appointment of key leadership positions and an oversubscribed follow-on offering in the fourth quarter, this progress positions us for success in 2022 and beyond.
  • Initiated accrual in PICCOLO, a single-arm study of mirvetuximab monotherapy in FR-high recurrent platinum-sensitive ovarian cancer.
  • ImmunoGen expects that its current cash, combined with anticipated product and collaboration revenues, will fund operations into 2024.

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

Retrieved on: 
Giovedì, Gennaio 20, 2022
MSD, Society of Gynecologic Oncology, Patient, Cancer, Union, Gynecologic Oncology (journal), Population, The New England Journal of Medicine, Safety, Paclitaxel, HIV disease progression rates, Pembrolizumab, Merck, LEAP, Radiation, Clinical research, Progression-free survival, PFS, Doxorubicin, Merck & Co., SGO, Eisai, Immunotherapy, Senior, ORR, Pharmaceutical industry, Medicine

(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy.

Key Points: 
  • (1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy.
  • Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.
  • "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."
  • LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status.

Sonoro Announces Closing of $3,000,000 Private Placement and Commencement of 10,000 Meter Drilling Program

Retrieved on: 
Martedì, Dicembre 21, 2021
Multilateral, Mineral resource estimation, SGO, Policy, Gold, GLOBE, Minority, Record, Board, IA, CEO, IBK, GOLD, MI, IS, Program, Unit, TSX Venture Exchange, Company, Capital market, Economics, PI, Offering, Maintenance, Silver, NEWS, Security (finance), Cryptocurrency, Uranium, Finder

VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce the closing of its previously announced non-brokered private placement of 16,666,667 units (the “Units”) at $0.18 per unit, for aggregate gross proceeds of $3,000,000 (the “Offering”). Each Unit consists of one Sonoro Common Share and one Share Purchase Warrant. Each warrant entitles the holder to purchase one additional Sonoro Common Share for a period of two years from the closing date at an exercise price of $0.30 per share.

Key Points: 
  • Each warrant entitles the holder to purchase one additional Sonoro Common Share for a period of two years from the closing date at an exercise price of $0.30 per share.
  • The Offering has received conditional acceptance from the TSX Venture Exchange but remains subject to receipt of final approval from the TSX Venture Exchange.
  • Sonoros President and CEO, Kenneth MacLeod, stated, We are excited to have commenced the next phase of drilling and anticipate another successful program.
  • I am also very pleased we have resumed drilling and are assessing the potential for higher-grade near-surface gold and silver mineralization.

Sonoro Files Cerro Caliche Preliminary Economic Assessment on SEDAR

Retrieved on: 
Venerdì, Ottobre 29, 2021
Techno-economic assessment, PEA, Integrity, Commission, Competence, Industry, SGO, National instrument, IRR, Integration competency center, Gold, AISC, Nature, Silver, Record, Company, National Instrument 43-101, Micon, Board, Technical report, Qualified person (European Union), Foodservice Equipment & Supplies, News, Project, Construction management, Engineering design process, GLOBE, LOM, NPV, Mining, Animal, Palladium, Printed circuit board, Uranium

VANCOUVER, British Columbia, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the filing of a technical report titled Preliminary Economic Assessment of the Cerro Caliche Project, Sonora, Mexico (the PEA) with an effective date of September 15, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the filing of a technical report titled Preliminary Economic Assessment of the Cerro Caliche Project, Sonora, Mexico (the PEA) with an effective date of September 15, 2021.
  • William Lewis, P.Geo., of Micon International Limited of Toronto, Ontario (Micon) was the Qualified Person responsible for the updated mineral resources estimate.
  • William Lewis, P.Geo., was responsible for the updated Cerro Caliche Mineral Resource Estimate and, along with David Salari, P.Eng., has approved the information pertaining to the Cerro Caliche Project in this news release.
  • Sonoro Gold Corp. is a publicly listed exploration and development company holding the near development stage Cerro Caliche project and the exploration stage San Marcial properties in Sonora State, Mexico.

Sonoro Gold Announces 10,000-Meter Drilling Program at Cerro Caliche

Retrieved on: 
Lunedì, Ottobre 25, 2021
Map, La, Magdalena, SGO, Exploration, Silver, Buena, New Jersey, Veta, Company, Colorado, Intention, Economics, CEO, Mineral resource estimation, Gold, Program, GLOBE, Cabeza, Uranium, Road

VANCOUVER, British Columbia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the intention to resume drilling at the Companys Cerro Caliche gold project in Sonora State, Mexico.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (Sonoro or the Company) is pleased to announce the intention to resume drilling at the Companys Cerro Caliche gold project in Sonora State, Mexico.
  • An additional 1,800-meters of drilling is targeted along the Buena Suerte/San Quintn Corridor (D) to the south of Buena Suerte.
  • Drilling will also focus on extending mineralization at two zones excluded from the updated resource estimate due to lack of required drilling density.
  • Sonoros President and CEO, Kenneth MacLeod, commented, This program has been under development since we paused drilling in May 2021.

The Foundation for Women's Cancer Launches Move the Message, a National Crusade to Increase Awareness of Gynecologic Cancers, Starting with Historically Marginalized Communities, Through Dissemination of Critical Resources to Drive Earlier Detection & Dia

Retrieved on: 
Giovedì, Settembre 30, 2021
Vulvar cancer, Cancer, Exercise, Diagnosis, Gynecologic Oncology (journal), Walking, Oncology nursing, Volunteering, Patient, Society of Gynecologic Oncology, Physician, MD, FWC, University, Gynaecology, Woman, Obstetrics, Awareness, Ginger, Risk, Society, Research, Message, Color, SGO, Memorial Sloan Kettering Cancer Center, Foundation, Education, Birth control, Medicine

These resources are easy to access at www.movethemessage.org for both the community at large as well as physicians to share with their patients.

Key Points: 
  • These resources are easy to access at www.movethemessage.org for both the community at large as well as physicians to share with their patients.
  • The lack of information and access to resources about gynecologic cancers is further magnified in marginalized populations.
  • The Society of Gynecologic Oncology (SGO)is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.
  • The Foundation for Women's Cancer (FWC) is dedicated to increasing public awareness of gynecologic cancer risk, prevention, early detection, and optimal treatment.

Sonoro Announces Positive PEA Results and Updated Mineral Resource Estimate for the Cerro Caliche Gold Project Which Demonstrates a Pre-Tax NPV of US$68.7 Million and an IRR of 52.7%

Retrieved on: 
Mercoledì, Settembre 15, 2021
Techno-economic assessment, IRR, CEO, National instrument, SEDAR, NPV, Mining, Mineral resource estimation, AISC, SGO, National Instrument 43-101, Silver, GLOBE, PEA, LOM, Nature, Goal, Management, News, Gold, Uranium, Palladium, Printed circuit board

Pre-Tax NPV (5% discount rate) of US$68.7 million and an IRR of 52.7% with a price of US$1,750 per ounce of gold and US$22.00 per ounce of silver.

Key Points: 
  • Pre-Tax NPV (5% discount rate) of US$68.7 million and an IRR of 52.7% with a price of US$1,750 per ounce of gold and US$22.00 per ounce of silver.
  • Gold recovery of 74% and silver recovery of 27% produced from a 3-stage crushing circuit, crushing the ore to p80 of .
  • Updated Mineral Resource Estimate Highlights at 0.207 g/t Au Cut-off:
    Measured and Indicated Mineral Resources of 349,000 ounces of gold at a 0.41 g/t Au grade.
  • The PEA really highlights the intrinsic value and potential economic viability of the Cerro Caliche project, said Mel Herdrick, VP Exploration of Sonoro Gold.

Sonoro Reports Surface Sampling Exposed Multiple Vein Windows Over 750 Meter Extension to Buena Suerte and El Colorado Zones

Retrieved on: 
Lunedì, Agosto 30, 2021
Company, BV, Record, Gold, SGO, Program, La, National instrument, GPS, Acid, GLOBE, ICP, Economics, National Instrument 43-101, PEA, Buena, New Jersey, Exploration, Autumn, Jose Cuervo, Sample, Bureau Veritas, Vein, Silver, Board, QA/QC, Techno-economic assessment, News, CEO, Â, Soil, Uranium, Sintering, Granite, Mining

The new results further confirmed material extensions of up to 750 meters over two southern linear structural corridors at the Buena Suerte and El Colorado zones.

Key Points: 
  • The new results further confirmed material extensions of up to 750 meters over two southern linear structural corridors at the Buena Suerte and El Colorado zones.
  • The sampling results also revealed oxide gold mineralized windows among the two southern structural corridors.
  • The windows were accessed via recently built road cuts and drill site excavations and future sampling will investigate potential continuation and extensions.
  • Mapping and sampling are currently underway at La Espaola to quantify the size of the exposed vein.